Device Trial Radar · NCT05674240
Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Dec 6, 2022
Primary completion
Mar 20, 2026
Study completion Mar 20, 2026
Sponsor
- Lead sponsor
- Wake Forest University Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 6, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.
Conditions
- Cancer Pain
- Chronic Pain
- Cancer Associated Pain
- Neuropathic Pain
Interventions
Intrathecal Targeted Drug DeliveryDevice
Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
Conservative medical managementCombination product
Including physical therapy, oral or transdermal medications and injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Pain Intensity from Screening through 3-MonthsTime frame: 3-Months
- Change in Pain Interference from Screening through 3-MonthsTime frame: 3-Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Advocate Aurora Health
Oshkosh, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.